Table 2.
Cohort characteristics
| Variables | Distribution (%) |
|---|---|
| Age | |
| <55 | 20 (19) |
| 55–64 | 53 (51) |
| ≥65 | 31 (30) |
| Pretreatment PSA | |
| ≤4.0 | 24 (23) |
| 4.1–10.0 | 70 (67) |
| >10.0 | 10 (10) |
| Clinical Stage | |
| T1c | 94 (90) |
| T2a | 10 (10) |
| Biopsy Gleason Score | |
| ≤6 | 71 (68) |
| 3 + 4 | 19 (18) |
| 4 + 3 | 8 (8) |
| 8–10 | 6 (6) |
| Cores Positive | |
| ≤2 | 57 (55) |
| 3–6 | 35 (34) |
| ≥7 | 12 (11) |
| Maximum Percent Per Core | |
| ≤50 | 80 (77) |
| >50 | 24 (23) |
| Pathologic Stage | |
| pT2a | 23 (22) |
| pT2b | 6 (6) |
| pT2c | 41 (39) |
| pT3a | 23 (22) |
| pT3b | 10 (10) |
| pT4 | 1 (1) |
| Pathologic Gleason Score | |
| ≤6 | 50 (48) |
| 3 + 4 | 34 (33) |
| 4 + 3 | 13 (12) |
| 8–10 | 7 (7) |
| Pathologic Maximum Tumor Diameter (cm) | |
| <1 | 18 (17) |
| 1.0–1.9 | 42 (40) |
| 2.0–2.9 | 29 (28) |
| ≥3.0 | 15 (15) |
PSA, prostate-specific antigen.